Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guangzhou Kingmed Diagnostics Group Co's EBIT per Share for the
three
months ended in Mar. 2026 was ¥0.14.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-0.15.
During the past 12 months, the average EBIT per Share Growth Rate of Guangzhou Kingmed Diagnostics Group Co was -43.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -59.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -38.60% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 10.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
SHSE:603882'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -59.4 Med: -4.25 Max: 98.7
Current: -59.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Guangzhou Kingmed Diagnostics Group Co was 98.70% per year. The lowest was -59.40% per year. And the median was -4.25% per year.
SHSE:603882's 3-Year EBIT Growth Rate is ranked worse than 96.34% of 164
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.1
vs SHSE:603882: -59.40
Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Guangzhou Kingmed Diagnostics Group Co EBIT per Share Related Terms
Guangzhou Kingmed Diagnostics Group Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Kingmed Diagnostics Group Co EBIT per Share Chart
Guangzhou Kingmed Diagnostics Group Co Annual Data
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.15
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) has a EBIT per Share of ¥-0.15 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Guangzhou Kingmed Diagnostics Group Co and its competitors. According to the industry distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #158 out of 164 companies in the Medical Diagnostics & Research industry, placing it in the top 96.3%.
Is Guangzhou Kingmed Diagnostics Group Co's EBIT per Share too high?
Guangzhou Kingmed Diagnostics Group Co's current EBIT per Share is ¥-0.15. Based on the distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #158 out of 164 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Guangzhou Kingmed Diagnostics Group Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Kingmed Diagnostics Group Co's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #158 out of 164 companies for EBIT per Share. This places Guangzhou Kingmed Diagnostics Group Co in the lower half of its industry. The industry median EBIT per Share is 13.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.10, based on 164 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Guangzhou Kingmed Diagnostics Group Co and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou Kingmed Diagnostics Group Co's current EBIT per Share is ¥-0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Kingmed Diagnostics Group Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) is currently considered Fairly Valued. The stock's GF Value™ is ¥28.03, compared to a current price of ¥26.44 — trading 5.7% below its estimated fair value. The current EBIT per Share is ¥-0.15. Guangzhou Kingmed Diagnostics Group Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Guangzhou Kingmed Diagnostics Group Co (SHSE:603882), the current EBIT per Share is ¥-0.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co stock appears to be undervalued.
The current stock price of ¥26.44 is trading 5.7% below its estimated GF Value™ of ¥28.03.
GuruFocus considers Guangzhou Kingmed Diagnostics Group Co to be Fairly Valued.
Key valuation signals for SHSE:603882:
EBIT per Share: ¥-0.15
GF Value™: ¥28.03 vs. price of ¥26.44 (5.7% below fair value)
No single metric tells the full story. See the SHSE:603882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Kingmed Diagnostics Group Co Business Description
Founded in 1994, KingMed is the largest independent clinical laboratory in China. It was listed on the Shanghai Stock Exchange in 2017. As of 2024, KingMed has 50 centralized labs and provides over 4000 test items. Over 90% of its total revenue comes from clinical diagnostics. Furthermore, KingMed has been actively investing in its cold chain logistics. Its service network covers the most intensely populated areas in China.
74GF Score
Get the complete analysis for SHSE:603882
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603882 has been successfully added to your 
